Etanercept in psoriatic arthritis

Journal of Rheumatology

Volumn 39, Issue SUPPL. 89, 2012, Pages 74-76

  Spadaro, Antonio ^a   Lubrano, Ennio ^b   Ferrara, Nicola ^b   Scarpa, Raffaele ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Etanercept; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BACKACHE; BINDING SITE; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; INFLAMMATORY PAIN; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SPONDYLOARTHROPATHY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; IMMUNOLOGY; METABOLISM; RADIOGRAPHY; REVIEW; TIME; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864407871     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120250     Document Type: Conference Paper

References (15)

1. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67.
2. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis; a randomised trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
3. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis. Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
4. Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010;37:1221-7.
5. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009;11:R52.
6. Lubrano E, Spadaro A, Marchesoni A, Olivieri I, Scarpa R, D'Angelo S, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011;29:80-4.
7. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;2;340:c147.
8. Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group Register. Ann Rheum Dis 2008;67:364-9. (Pubitemid 351281272)
9. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008;7:1650-1.
10. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
11. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035-50.
12. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32:2183-5. (Pubitemid 41587865)
13. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66:1393-7. (Pubitemid 47492489)
14. Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology 2010;49:1107-11.
15. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70.